The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

Philip S. Helliwell, Oliver FitzGerald, Jaap Fransen, Dafna D. Gladman, Gerald G. Kreuger, Kristina Callis-Duffin, Neil McHugh, Philip J. Mease, Vibeke Strand, Robin Waxman, Valderilio Feijo Azevedo, Adriana Beltran Ostos, Sueli Carneiro, Alberto Cauli Luis R Espinoza, John A. Flynn, Nada Hassan, Paul Healy, Eduardo Mario Kerzberg, Yun Jong Lee, Ennio Lubrano & 16 others Antonio Marchesoni, Helena Marzo-Ortega, Giovanni Porru, Elvia G. Moreta, Peter Nash, Helena Raffayova, Roberto Ranza, Siba P. Raychaudhuri, Euthalia Roussou, Raphael Scarpa, Yeong Wook Song, Enrique R. Soriano, Paul P. Tak, Ilona Ujfalussy, Kurt De Vlam, Jessica A. Walsh

Research output: Contribution to journalArticle

Abstract

Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods: Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression ( psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results: 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease ( psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions: Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.

Original languageEnglish (US)
Pages (from-to)986-991
Number of pages6
JournalAnnals of the Rheumatic Diseases
Volume72
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Psoriatic Arthritis
Composite materials
Area Under Curve
Ambulatory Care
Psoriasis
Skin Diseases
Linear regression
Linear Models
Rheumatoid Arthritis
Randomized Controlled Trials
Skin

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Cite this

Helliwell, P. S., FitzGerald, O., Fransen, J., Gladman, D. D., Kreuger, G. G., Callis-Duffin, K., ... Walsh, J. A. (2013). The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Annals of the Rheumatic Diseases, 72(6), 986-991. https://doi.org/10.1136/annrheumdis-2012-201341

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). / Helliwell, Philip S.; FitzGerald, Oliver; Fransen, Jaap; Gladman, Dafna D.; Kreuger, Gerald G.; Callis-Duffin, Kristina; McHugh, Neil; Mease, Philip J.; Strand, Vibeke; Waxman, Robin; Azevedo, Valderilio Feijo; Ostos, Adriana Beltran; Carneiro, Sueli; Espinoza, Alberto Cauli Luis R; Flynn, John A.; Hassan, Nada; Healy, Paul; Kerzberg, Eduardo Mario; Lee, Yun Jong; Lubrano, Ennio; Marchesoni, Antonio; Marzo-Ortega, Helena; Porru, Giovanni; Moreta, Elvia G.; Nash, Peter; Raffayova, Helena; Ranza, Roberto; Raychaudhuri, Siba P.; Roussou, Euthalia; Scarpa, Raphael; Song, Yeong Wook; Soriano, Enrique R.; Tak, Paul P.; Ujfalussy, Ilona; De Vlam, Kurt; Walsh, Jessica A.

In: Annals of the Rheumatic Diseases, Vol. 72, No. 6, 06.2013, p. 986-991.

Research output: Contribution to journalArticle

Helliwell, PS, FitzGerald, O, Fransen, J, Gladman, DD, Kreuger, GG, Callis-Duffin, K, McHugh, N, Mease, PJ, Strand, V, Waxman, R, Azevedo, VF, Ostos, AB, Carneiro, S, Espinoza, ACLR, Flynn, JA, Hassan, N, Healy, P, Kerzberg, EM, Lee, YJ, Lubrano, E, Marchesoni, A, Marzo-Ortega, H, Porru, G, Moreta, EG, Nash, P, Raffayova, H, Ranza, R, Raychaudhuri, SP, Roussou, E, Scarpa, R, Song, YW, Soriano, ER, Tak, PP, Ujfalussy, I, De Vlam, K & Walsh, JA 2013, 'The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)', Annals of the Rheumatic Diseases, vol. 72, no. 6, pp. 986-991. https://doi.org/10.1136/annrheumdis-2012-201341
Helliwell, Philip S. ; FitzGerald, Oliver ; Fransen, Jaap ; Gladman, Dafna D. ; Kreuger, Gerald G. ; Callis-Duffin, Kristina ; McHugh, Neil ; Mease, Philip J. ; Strand, Vibeke ; Waxman, Robin ; Azevedo, Valderilio Feijo ; Ostos, Adriana Beltran ; Carneiro, Sueli ; Espinoza, Alberto Cauli Luis R ; Flynn, John A. ; Hassan, Nada ; Healy, Paul ; Kerzberg, Eduardo Mario ; Lee, Yun Jong ; Lubrano, Ennio ; Marchesoni, Antonio ; Marzo-Ortega, Helena ; Porru, Giovanni ; Moreta, Elvia G. ; Nash, Peter ; Raffayova, Helena ; Ranza, Roberto ; Raychaudhuri, Siba P. ; Roussou, Euthalia ; Scarpa, Raphael ; Song, Yeong Wook ; Soriano, Enrique R. ; Tak, Paul P. ; Ujfalussy, Ilona ; De Vlam, Kurt ; Walsh, Jessica A. / The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). In: Annals of the Rheumatic Diseases. 2013 ; Vol. 72, No. 6. pp. 986-991.
@article{719dcdbb7b5b44ffb463edf00d0fecda,
title = "The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)",
abstract = "Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods: Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression ( psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results: 161/503 (32{\%}) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95{\%} CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease ( psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions: Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.",
author = "Helliwell, {Philip S.} and Oliver FitzGerald and Jaap Fransen and Gladman, {Dafna D.} and Kreuger, {Gerald G.} and Kristina Callis-Duffin and Neil McHugh and Mease, {Philip J.} and Vibeke Strand and Robin Waxman and Azevedo, {Valderilio Feijo} and Ostos, {Adriana Beltran} and Sueli Carneiro and Espinoza, {Alberto Cauli Luis R} and Flynn, {John A.} and Nada Hassan and Paul Healy and Kerzberg, {Eduardo Mario} and Lee, {Yun Jong} and Ennio Lubrano and Antonio Marchesoni and Helena Marzo-Ortega and Giovanni Porru and Moreta, {Elvia G.} and Peter Nash and Helena Raffayova and Roberto Ranza and Raychaudhuri, {Siba P.} and Euthalia Roussou and Raphael Scarpa and Song, {Yeong Wook} and Soriano, {Enrique R.} and Tak, {Paul P.} and Ilona Ujfalussy and {De Vlam}, Kurt and Walsh, {Jessica A.}",
year = "2013",
month = "6",
doi = "10.1136/annrheumdis-2012-201341",
language = "English (US)",
volume = "72",
pages = "986--991",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

AU - Helliwell, Philip S.

AU - FitzGerald, Oliver

AU - Fransen, Jaap

AU - Gladman, Dafna D.

AU - Kreuger, Gerald G.

AU - Callis-Duffin, Kristina

AU - McHugh, Neil

AU - Mease, Philip J.

AU - Strand, Vibeke

AU - Waxman, Robin

AU - Azevedo, Valderilio Feijo

AU - Ostos, Adriana Beltran

AU - Carneiro, Sueli

AU - Espinoza, Alberto Cauli Luis R

AU - Flynn, John A.

AU - Hassan, Nada

AU - Healy, Paul

AU - Kerzberg, Eduardo Mario

AU - Lee, Yun Jong

AU - Lubrano, Ennio

AU - Marchesoni, Antonio

AU - Marzo-Ortega, Helena

AU - Porru, Giovanni

AU - Moreta, Elvia G.

AU - Nash, Peter

AU - Raffayova, Helena

AU - Ranza, Roberto

AU - Raychaudhuri, Siba P.

AU - Roussou, Euthalia

AU - Scarpa, Raphael

AU - Song, Yeong Wook

AU - Soriano, Enrique R.

AU - Tak, Paul P.

AU - Ujfalussy, Ilona

AU - De Vlam, Kurt

AU - Walsh, Jessica A.

PY - 2013/6

Y1 - 2013/6

N2 - Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods: Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression ( psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results: 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease ( psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions: Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.

AB - Objective: To develop new composite disease activity indices for psoriatic arthritis (PsA). Methods: Data from routine clinic visits at multiple centres were collected in a systematic manner. Data included all domains identified as important in randomised controlled trials in PsA. Decisions to change treatment were used as surrogates for high disease activity. New indices were developed by multiple linear regression ( psoriatic arthritis disease activity score: PASDAS) and empirically, utilising physician-defined cut-offs for disease activity (arithmetic mean of desirability functions: AMDF). These were compared with existing composite measures: Composite Psoriatic arthritis Disease Activity Index (CPDAI), Disease Activity for PSoriatic Arthritis (DAPSA), and Disease Activity Score for rheumatoid arthritis (DAS28). Results: 161/503 (32%) subjects had treatment changes. Although all measures performed well, compared with existing indices, PASDAS was better able to discriminate between high and low disease activity (area under receiver operating curves (ROC)) curve with 95% CI: PASDAS 0.773 (0.723, 0.822); AMDF 0.730 (0.680, 0.780); CPDAI 0.719 (0.668, 0.770); DAPSA 0.710 (0.654, 0.766); DAS28 0.736 (0.680, 0.792). All measures were able to discriminate between disease activity states in patients with oligoarthritis, although area under the receiver operating curves (AUC) were generally smaller. In patients with severe skin disease ( psoriasis area and severity index >10) both nonparametric and AUC curve statistics were nonsignificant for all measures. Conclusions: Two new composite measures to assess disease activity in PsA have been developed. Further testing in other datasets, including comparison with existing measures, is required to validate these instruments.

UR - http://www.scopus.com/inward/record.url?scp=84877636515&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84877636515&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2012-201341

DO - 10.1136/annrheumdis-2012-201341

M3 - Article

VL - 72

SP - 986

EP - 991

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 6

ER -